DelveInsight’s “Cystic Fibrosis Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Cystic Fibrosis market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The report covers emerging Cystic Fibrosis drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Cystic Fibrosis treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Cystic Fibrosis: An Overview
Cystic fibrosis (CF) is an autosomal recessive condition known as brought on by mutations in the Cystic Fibrosis transmembrane conductance regulator (CFTR) gene. F508del is the most prevalent variation reported globally, but there are over 2,000 others, although not all of these are disease-causing.
Cystic Fibrosis is usually diagnosed in childhood, however, adults with no symptoms (or mild symptoms) during their youth can still be found to have the disease. The signs and symptoms of Cystic Fibrosis generally begin to occur around 6–8 months after birth, though this can differ significantly from person to person. Symptoms tend to differ depending on age and can affect various areas of the body.
Tests to diagnose cystic fibrosis include newborn screening, which is a genetic test to check for a gene defect, and/or a blood test to screen for pancreatic problems. Sweat tests can be done after initial testing, to confirm the diagnosis. This test involves analyzing a sweat sample to see how much salt it contains. An abnormally high level may indicate Cystic Fibrosis. If Cystic Fibrosis is confirmed, other tests may be carried out to check for complications. These may include ultrasound scans, X-rays, and a biopsy.
Currently, there is no cure for cystic fibrosis, but treatment can ease symptoms, reduce complications, and improve quality of life. Management of Cystic Fibrosis requires drug therapy, extensive physiotherapy, and nutritional support. CFTR modulators like, KALYDECO (ivacaftor), TRIKAFTA/KAFTRIO, ORKAMBI (lumacaftor/ivacaftor), and SYMDEKO/SYMKEVI (tezacaftor/ivacaftor) are some of the medication approved by the regulatory bodies for patients with Cystic Fibrosis.
Cystic Fibrosis Market Key Facts
The United States accounts for the highest market size of Cystic Fibrosis approximately 80% of the total market size in 7MM in 2021, in comparison to the other major markets i.e., the EU5 countries (the United Kingdom, Germany, Italy, France, and Spain), and Japan.
Among the EU5 countries, the United Kingdom had the highest market size with USD 778 million in 2021, while Spain had the lowest market size for Cystic Fibrosis with USD 50 million in 2021.
The market size for Cystic Fibrosis in Japan was estimated to be USD 0.3 Million in 2021, which accounts for less than 1% of the total 7MM market.
With the expected launch of upcoming therapies, VX-121/TEZ/D-IVA and Ensifentrine, the total market size of Cystic Fibrosis is expected to change in the upcoming years.
In the assessment done by DelveInsight, the estimated total diagnosed prevalent cases of Cystic Fibrosis in the 7MM was 65,519 cases in 2021.
The highest total diagnosed prevalent cases of Cystic Fibrosis were registered in the US in 2021 (32,100 cases), which are expected to show a rise in the future.
Among the European countries, the United Kingdom had the highest diagnosed prevalent cases of CF with 10,922 cases, followed by France, which had diagnosed prevalent cases of 7,418 in 2021. On the other hand, Spain had the lowest diagnosed prevalent cases (2,520 cases).
Japan had 47 total diagnosed prevalent cases of Cystic Fibrosis in 2021, accounting for approximately 0.1% of the 7MM.
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Cystic Fibrosis pipeline therapies. It also thoroughly assesses the Cystic Fibrosis market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete details of the market trend for each marketed Cystic Fibrosis drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Cystic Fibrosis Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted Cystic Fibrosis epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Cystic Fibrosis epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders.
The Report Covers the Cystic Fibrosis Epidemiology, Segmented as –
Total Diagnosed Prevalent Cases of Cystic Fibrosis
Gender-specific Diagnosed Prevalent Cases of Cystic Fibrosis
Age-specific Diagnosed Prevalent Cases of Cystic Fibrosis
Type-specific Diagnosed Prevalent Cases of Cystic Fibrosis
Cystic Fibrosis Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Cystic Fibrosis market or expected to be launched during the study period. The analysis covers the Cystic Fibrosis market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares Cystic Fibrosis drugs based on their sale and market share.
The report also covers the Cystic Fibrosis pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Cystic Fibrosis companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Cystic Fibrosis Market Will Evolve and Grow by 2032 @
Cystic Fibrosis Therapeutics Analysis
Several major pharma and biotech companies are developing therapies for Cystic Fibrosis. Currently, Algi Pharma is leading the therapeutics market with its Cystic Fibrosis drug candidates in the most advanced stage of clinical development.
Cystic Fibrosis Companies Actively Working in the Therapeutics Market Include
Krystal Biotech, Vertex Pharmaceuticals, Translate Bio, Novartis, Algi Pharma, Verona Pharma, Atlantic Healthcare, Calithera Biosciences, Horizon Therapeutics, Santhera Pharmaceuticals, Reveragen Biopharma, Spli Sense, GlaxoSmithKline, EmphyCorp, Abbvie, Galapagos NV, Vertex Pharmaceuticals, PathBio Analytics, AstraZeneca, AxentisPharma AG, and many others.
Emerging and Marketed Cystic Fibrosis Therapies Covered in the Report Include:
OligoG: Algi Pharma
Ensifentrine: Verona Pharma
MRT5005: Translate Bio
CB280: Calithera Biosciences
KB407 : Krystal Biotech
And Many More
The Report Covers an In-depth Assessment of Emerging Drugs and key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Cystic Fibrosis Competitive Intelligence Analysis
4. Cystic Fibrosis Market Overview at a Glance
5. Cystic Fibrosis Disease Background and Overview
6. Cystic Fibrosis Patient Journey
7. Cystic Fibrosis Patient Population and Epidemiology Trends (In the US, EU5, and Japan)
8. Cystic Fibrosis Treatment Algorithm, Current Treatment, and Medical Practices
9. Cystic Fibrosis Unmet Needs
10. Key Endpoints of Cystic Fibrosis Treatment
11. Cystic Fibrosis Marketed Therapies
12. Cystic Fibrosis Emerging Drugs and Latest Therapeutic Advances
13. Cystic Fibrosis Seven Major Market Analysis
14. Attribute Analysis
15. Cystic Fibrosis Market Outlook (In US, EU5, and Japan)
16. Cystic Fibrosis Companies Active in the Market
17. Cystic Fibrosis Access and Reimbursement Overview
18. KOL Views on the Cystic Fibrosis Market
19. Cystic Fibrosis Market Drivers
20. Cystic Fibrosis Market Barriers
22. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Other Trending Healthcare Reports by DelveInsight
“Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the historical and forecasted epidemiology as well as the Substance (Drug) Abuse market size, share, trends, and growth analysis in the seven major markets (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan. Moreover, it also covers the current treatment practices, emerging drugs, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the Substance (Drug) Abuse market.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States